Pulmatrix has announced that Robert Clarke will succeed Robert Connelly as the company’s Chief Executive Officer. Clarke has been with the company, which is developing inhaled drugs based on its proprietary iSPERSE (inhaled small particles easily respirable and emitted) platform, since 2004 as VP of Research & Development and as Chief Scientific Officer.
Clarke commented, “I am excited to take on this leadership role at Pulmatrix at such a pivotal time, as we advance our novel platform and therapeutics with breakthrough potential to address unmet needs of patients with chronic respiratory diseases. Pulmatrix has tremendous potential to develop multiple novel product opportunities from our iSPERSE platform, including the advancement of our proprietary iCALM therapies through clinical trials.”
Board member Terry McGuire said, “Pulmatrix is on a very promising clinical development path and Bob Clarke is the ideal choice to lead it through this important stage. We have incredible confidence in Bob Clarke’s ability to take Pulmatrix to the next level, as his accomplishments in discovering the novel efficacy of iCALM and expanding the capabilities of the iSPERSE platform have created a wide range of valuable product and partnering opportunities for the company. We also recognize Bob Connelly’s significant contribution to building Pulmatrix into a clinical stage biotech with several very promising drugs in development for chronic respiratory diseases, and we look forward to his continuing involvement on the Pulmatrix board.”
According to the company, Connelly is leaving to start a new company. WikiCell Designs, co-founded with David Edwards of Harvard, will develop edible packaging.
Read the Pulmatrix press release.
